Introduction {#sec1}
============

Immune-mediated inflammatory diseases (IMID) are characterised by systemic inflammation and immune dysregulation, with three of the most common and functionally severe IMID in Canada being inflammatory bowel disease (IBD), multiple sclerosis (MS) and rheumatoid arthritis (RA; Wong *et al*., [@ref69]; Coward *et al*., [@ref18]; Gilmour *et al*., [@ref22]). Mental health disorders, particularly anxiety and depressive disorders are more prevalent among individuals with IMID relative to the general population (Matcham *et al*., [@ref43], [@ref41]; Tribbick *et al*., [@ref64]; Marrie *et al*., [@ref42]) and those experiencing comorbid mental health difficulties exhibit poorer functional outcomes, including lower employment rates (Gilworth *et al*., [@ref23]; De Boer *et al*., [@ref19]), greater disability (Bombardier *et al*., [@ref10]; Chan *et al*., [@ref15]) and lower quality of life (Matcham *et al*., [@ref44]; Kochar *et al*., [@ref34]; Amtmann *et al*., [@ref2]).

The high co-occurrence of mental health disorders in IMID populations is likely multifactorial in aetiology. The onset and experience of disease is a stressor, capable of producing or exacerbating mental health concerns (Sokal *et al*., [@ref60]). Conversely, symptomatology associated with poor mental health (e.g., chronic sleep difficulties) may also trigger physical health problems (Leng *et al*., [@ref36]). Some evidence suggests mutual points of origin between IMID and mental health disorders such as depression (Krishnadas and Cavanagh, [@ref35]), including hypothalamic-pituitary-adrenal axis overactivity (McEwen, [@ref45]), upregulation of cytokine-induced inflammatory processes (Kendall-Tackett, [@ref32]) and genetic mutations (Euesden *et al*., [@ref20]).

Although personality disorders (PDs) are elevated among those with various chronic physical health conditions (Quirk *et al*., [@ref53]) and potentially complicate the management of an IMID, they have been largely overlooked in the IMID literature. In part, this is due to taxonomic concerns with the diagnosis of a PD. There are shared characteristics, albeit varying in salience to the presentation, among PDs (e.g., hostility, evident in paranoid, narcissistic and antisocial PD; Westen *et al*., [@ref68]). Further, given personality pathology is an extension of normative personality functioning, distinction is open to bias (Bakker, [@ref5]). However, recent emphasis has been placed on improving empirically based delineation of personality dysfunction, allowing for new avenues of investigation.

In the existing literature, neuroticism has been reported in persons with IBD and RA (Hyphantis *et al*., [@ref28]; Tosic-Golubovic *et al*., [@ref63]), obsessive-compulsive personality characteristics have been reported in persons with RA and MS (Marcenaro *et al*., [@ref40]; Mohamadi *et al*., [@ref48]), and indications of Cluster B personality styles (i.e., narcissistic, borderline, histrionic) have been described in persons with MS and RA (Marcenaro *et al*., [@ref40]; Incerti *et al*., [@ref29]). However, much of this research has relied on personality inventories rather than clinician-based diagnoses, given the diagnostic issues, and population-based estimates have been particularly limited (Hyphantis *et al*., [@ref28]; Vidal *et al*., [@ref66]; Incerti *et al*., [@ref29]). As such, differences in study design have limited comparability across diseases, which may drive apparent discrepancies between IMID conditions. For example, Harel *et al*. ([@ref25]) reported 3% of their MS sample presented with personality dysfunction, whereas Robertson *et al*. ([@ref55]) identified 60% of their IBD sample as non-normative in terms of a personality profile.

We aimed to examine the association between any PD and three IMID concurrently (IBD, MS and RA) in a large, population-based sample using physician-based administrative clinical data. Specifically, we compared the incidence over time of any PD in IMID cohorts and matched controls, and examined sociodemographic factors associated with PDs. We also assessed whether the incidence of any PD is increased in the 5 years before the diagnosis of IMID, as compared to a matched population and compared to the 5-years post-diagnosis.

Methods {#sec2}
=======

Setting {#sec2-1}
-------

This retrospective cohort study was conducted in Manitoba, Canada, a province with a population of approximately 1.3 million. Health care in Manitoba is universal and publically funded, and the province maintains administrative databases of all health services delivered; these data are collected at the time of service delivery. We accessed these databases through the Manitoba Population Research Data Repository at the Manitoba Centre for Health Policy. This study was approved by the University of Manitoba Health Research Ethics Board and data access was approved by the Manitoba Health Information Privacy Committee.

Data sources {#sec2-2}
------------

We used administrative databases for the period from April 1, 1984 (the earliest date available) to March 31, 2013 (latest date available at the time of study approval). The population registry includes sociodemographic data, dates of health care coverage, as well as residence location by postal code for each provincial resident eligible to receive health services. Since 1984, every Manitoba resident has been assigned a unique personal health identification number (PHIN). All physician claims and hospital records include the individual\'s unique PHIN. Physician claims data provide the date of service and one physician-assigned diagnosis per visit, using the International Classification of Diseases (ICD), 9th revision, Clinical Modification (ICD-9-CM). Hospital records data provide hospital admission and separation dates and information regarding hospital admissions, including up to 25 diagnoses using ICD-9-CM (and ICD-10-CA codes after 2004). We also identified outpatient prescription dispensations, including date, drug name and drug identification number (DIN) using the Drug Program Information Network (DPIN; beginning in 1995), which uses the World Health Organization\'s Anatomical Therapeutic Chemical (ATC) Classification System. To maintain confidentiality, databases were linked using anonymised unique identifiers at the individual level.

Study populations {#sec2-3}
-----------------

First, using validated case definitions we created cohorts of all Manitobans with IBD (Bernstein *et al*., [@ref9]), MS (Al-Sakran *et al*., [@ref1]) and RA (Hitchon *et al*., [@ref26]). The date of diagnosis, or index date, was defined as the date of the first health claim for the IMID condition during the study period. To identify true index dates and thereby incident cases of IMID, individuals with relevant health claims (that is, claims for IBD, MS or RA) 5 years before the date of their IMID diagnosis were excluded. Given the need to look back 5 years and availability of administrative data beginning in 1984, the earliest index dates occurred in 1989 and the last in 2011. We established cohorts matched 5:1 to each IMID participant on sex, year of birth within a range of ±5 years and region of residence as determined by the first three digits of the postal code. These matched cohorts excluded individuals with ICD-9-CM/ICD-10-CA diagnosis codes for IBD, demyelinating disease, RA and related disorders, and use of MS-specific disease-modifying therapies (which were part of the MS case definition). Each control was assigned the index date of its matched case.

For analyses involving pre- and post-IMID index comparisons in the incidence of any PD, we further restricted the study population. Specifically, we required the incident disease cases and their matched controls to have ⩾5.5 continuous years of data available before and after the index date; this allowed for a 5-year pre-index and 5-year post-index window, with the 6-month intervals before and after the index date comprising the index year. Thus index dates ranged from 1989 to 2008.

Personality disorders {#sec2-4}
---------------------

PDs were identified based on the presence of ⩾1 hospitalisation or physician claim with ICD-9-CM/10-CA codes 301, F21, F60, F61 and F69 (Chartier *et al*., [@ref16]; Beaulieu *et al*., [@ref8]). The case definition selection is intended to exclude those with personality changes secondary to medical conditions. To identify any incident PD, the first claim for the PD had to be preceded by 5 years with no PD claims as defined above (301, F21, F60, F61 and F69). Therefore incidence is reported from April 1, 1989 through March 31, 2012. To estimate lifetime (period) prevalence, once a person met the case definition for a PD, he or she was considered affected in all subsequent years if living in Manitoba. However, some individuals with a PD may experience periods of remission (Gunderson *et al*., [@ref24]). Therefore, we estimated the annual period prevalence of PDs through those requiring ongoing care each year; a person was only counted as an annual prevalent case if there was ⩾1 hospital or physician claims for the disorder in that year, otherwise, they were considered unaffected.

Covariates {#sec2-5}
----------

Covariates included sex (male as reference group), age (18--24, 25--44, 45--64, ⩾65; 18--24 years as reference group), socioeconomic status (SES, in quintiles; the highest quintile as reference group), region (urban, rural; rural as reference group) and annual number of visits to a physician unrelated to a psychiatric disorder. SES was determined through linking postal codes to dissemination-area level census data from Statistics Canada to derive the Socioeconomic Factor Index version 2 (SEFI-2), an indicator based on average household income, per cent of single parents households, unemployment rate and high school education rate, where higher scores indicate lower SES (Chateau, Metge, Prior, and Soodeen, [@ref17]). Urban regions encompassed Winnipeg (population \>600 000) and Brandon (population \>47 000). Models of incidence pre and post-IMID index also included a variable for index year (1999--2007 *v.* 1989--1998).

Analyses {#sec2-6}
--------

We summarised the sociodemographic characteristics of the study cohorts using descriptive statistics. We estimated the crude annual incidence, lifetime and annual period prevalence, and 95% confidence intervals (CI) of any PD for the disease cohorts (i.e., combined IMID, IBD, MS, RA) and their matched control cohorts. Estimates were age- and sex-standardised to the 2010 Canadian population. We then tested for differences in incidence rates of any PD between the disease cohorts and the matched cohorts using unadjusted and covariate-adjusted negative binomial regression models. These models included the natural logarithm of the number of person-years as an offset to account for variable follow-up, and the covariates defined above. Additional covariate-adjusted models included the interaction of cohort × year to assess if there was a significant difference in the temporal trend for the disease and matched cohorts. We report incidence rate ratios (IRR) and 95%CI for these models.

In the subgroup with 5 years of data before and after the IMID index date, we estimated the annual incidence of any PD in each year of the pre-index, index and post-index periods. We tested whether the temporal trends in the incidence of any PD changed within the pre- and post-index periods, and whether these trends differed between the pre- and post-index periods. We also compared whether the findings differed between the IMID and matched cohorts. Therefore we created multivariable negative binomial regression models that incorporated three main effects of cohort (IMID *v*. matched \[reference\]), period (pre-diagnosis \[reference\], diagnosis, post-diagnosis) and year (continuous variable from 1 to 5 in the pre-diagnosis and post-diagnosis periods, 0 for the year of diagnosis) as well as two-way interactions between cohort and period, and year and period, and a three-way interaction between cohort, period and year. These models also included covariates as described above. We conducted separate models for each IMID cohort.

Statistical analyses were performed using SAS V9.4 (SAS Institute Inc., Cary, NC.)

Results {#sec3}
=======

Study population {#sec3-1}
----------------

We identified 19 572 incident cases of IMID, including 6119 incident cases of IBD, 3514 incident cases of MS, and 10 206 incident cases of RA (Marrie *et al*., [@ref42]). The matched cohort comprised 97 727 persons, with 30 573 persons matched to the IBD cohort, 17 526 persons matched to the MS cohort, and 50 960 persons matched to the RA cohort. A majority of the sample was female (66.7%), with a mean age at diagnosis ranging from 40.8 (12.5) years for MS to 53.7 (16.0) years for RA ([Table 1](#tab01){ref-type="table"}). Table 1.Characteristics of the study cohorts and subgroupsCharacteristicsCombined IMIDCombined IMID matchesIBDIBD matchesMSMS matchesRARA matchesWhole population (index dates: 1989--2013)*n* 19 572 97 7276119 30 5733514 17 526 10 206 50 960Female: *n* (%) 13 053 (66.7) 65 185 (66.7)3330 (54.4) 16 642 (54.4)2544 (72.4) 12 697 (72.4)7369 (72.2) 36 793 (72.2)Age at diagnosis (yrs): mean ([s.d.]{.smallcaps})47.7 (17.0)47.7 (16.9)41.9 (17.0)41.9 (17.0)40.8 (12.5)40.8 (12.5)53.7 (16.0)53.7 (16.0)Duration (yrs) of follow-up from index date: median (IQR)9.67 (4.66, 15.5)9.51 (4.45, 15.5)9.98 (4.64, 16.0)9.69 (4.34, 15.9)10.3 (4.90, 16.1)10.5 (5.0, 16.3)9.19 (4.58, 14.8)9.05 (4.33, 14.9)Urban residence: *n* (%) 12 244 (62.6) 61 138 (62.6)4095 (66.9) 20 460 (66.9)2344 (66.7) 11 685 (66.7)5981 (58.6) 29 870 (58.6)Socioeconomic status−0.05 (0.95)−0.09 (0.99)−0.26 (0.91)−0.20 (0.88)−0.21 (0.89)−0.18 (0.87)0.05 (1.03)0.08 (1.00)Restricted subgroup (index dates: 1989--2008)*n* 12 141 65 4243766 20 3552190 12 3156350 33 584Female: *n* (%)8220 (67.7) 44 427 (67.9)2062 (54.7) 11 230 (55.2)1621 (74.0)9108 (74.0)4658 (77.2) 24 692 (73.5)Age at diagnosis (yrs): mean ([s.d.]{.smallcaps})47.0 (16.2)46.6 (16.0)41.5 (16.4)41.0 (15.9)40.2 (11.5)40.5 (11.7)52.7 (15.4)52.3 (15.3)Duration (yrs) of follow-up from index date: median (IQR)12.8 (9.0, 17.4)12.8 (9.0, 17.4)13.4 (9.3, 18.1)13.3 (9.2, 17.9)13.4 (9.4, 18.0)13.2 (9.3, 18.0)12.4 (8.8, 16.7)12.4 (8.8, 16.7)Urban residence: *n* (%)7495 (61.7) 40 809 (62.4)2491 (66.1) 13 545 (66.5)1435 (65.5)8172 (66.3)3681 (58.0) 19 637 (58.5)Socioeconomic status−0.11 (0.99)−0.06 (0.96)−0.28 (0.92)−0.20 (0.89)−0.27 (0.90)−0.20 (0.87)0.04 (1.00)0.08 (1.00)[^1][^2]

Prevalence and incidence of personality disorders {#sec3-2}
-------------------------------------------------

In 2011, the crude lifetime prevalence of any PD per 100 persons was higher in the combined IMID cohort (4.72; 95% CI: 4.38--5.09) than in the matched cohort (3.10; 95% CI: 2.98--3.24). After age and sex-standardisation, the lifetime prevalence of any PD remained 50% higher in the combined IMID than the matched cohort (prevalence ratio 1.51; 95% CI: 1.34--1.70). Similarly, the lifetime prevalence of any PD was elevated in the IBD, MS and RA cohorts as compared to their matched controls. In 2011, the standardised annual prevalence of any PD per 100 persons was almost two-fold higher in the combined IMID cohort (0.63; 95% CI: 0.42--0.94) than in the matched cohort (0.33; 95% CI: 0.26--0.41). The annual prevalence of any PD was also higher in the individual disease cohorts as compared to their matches (IBD: 0.64% *v*. 0.32%; MS: 0.69% *v*. 0.28%; RA: 0.46% *v*. 0.28%).

In 2011, the crude incidence of any PD per 100 person-years was higher in the combined IMID cohort (0.21; 95% CI: 0.14--0.30) than in the matched cohort (0.13; 95% CI: 0.11--0.16). After age and sex-standardisation the incidence of any PD remained non-significantly higher in the combined IMID cohort (IRR 1.48; 95% CI: 0.94--2.33). The incidence of any PD was also higher in the individual IMID cohorts (see [Fig. 1](#fig01){ref-type="fig"}). Fig. 1.Incidence of any personality disorder per 100 person-years, age and sex-standardized to the 2010 Canadian population, in disease cohorts and matched controls across study period. Absent lines are due to suppressed cells.

Sociodemographic factors associated with personality disorders {#sec3-3}
--------------------------------------------------------------

After adjusting for age, sex, year, SES, region and number of physician visits, the combined IMID cohort had a higher incidence of any PD than the matched cohort ([Table 2](#tab02){ref-type="table"}). Compared to the highest SES quintile, all lower SES quintiles were associated with an increased incidence of any PD. Compared to those living in a rural region, individuals living in an urban region had an increased incidence of any PD. Individuals aged 25--64 years had a lower incidence of any PD compared to those aged 18--24 years. The incidence of any PD declined slightly over time but there was no observed interaction between cohort and time. The findings were similar for each individual IMID ([Table 2](#tab02){ref-type="table"}). Table 2.Adjusted[^a^](#tfn2_1){ref-type="table-fn"} incidence rate ratios and 95% confidence intervals for the association between sociodemographic characteristics and any personality disorder among study cohortsCombined IMIDIBDMSRAVariableCohortMatches1.001.001.001.00IMID**1.72 (1.47--2.01)\*2.19 (1.69--2.84)\*1.79 (1.29--2.50)\*1.61 (1.29--1.99)\***SexMale1.001.001.001.00Female1.10 (0.95--1.28)1.22 (0.99--1.51)0.79 (0.57--1.11)1.06 (0.85--1.32)Age (years)18--241.001.001.001.0025--440.83 (0.67--1.02)0.85 (0.63--1.14)0.71 (0.44--1.13)0.69 (0.48--1.00)45--64**0.54 (0.43--0.68)\*0.56 (0.41--0.77)\*0.51 (0.32--0.82)\*0.42 (0.28--0.64)\***⩾650.98 (0.80--1.21)0.92 (0.66--1.29)1.03 (0.53--2.01)0.84 (0.57--1.24)Socioeconomic statusQuintile 1 (lowest)**2.39 (1.98--2.87)\*2.45 (1.78--3.38)\*2.90 (1.88--4.46)\*2.26 (1.74--2.93)\***Quintile 2**1.94 (1.60--2.35)\*2.09 (1.53--2.87)\***1.57 (0.99--2.49)**2.00 (1.53--2.62)\***Quintile 3**1.49 (1.22--1.82)\*1.45 (1.04--2.03)\***1.49 (0.94--2.35)**1.56 (1.18--2.07)\***Quintile 4**1.56 (1.29--1.89)\*1.58 (1.15--2.16)\*1.74 (1.15--2.63)\*1.48 (1.12--1.95)\***Quintile 5 (highest)1.001.001.001.00RegionRural1.001.001.001.00Urban**1.86 (1.64--2.11)\*1.56 (1.24--1.97)\*1.78 (1.32--2.41)\*2.02 (1.71--2.38)\***Year0.99 (0.98--1.00)**0.97 (0.95--1.00)\*0.97 (0.95--1.00)\***1.00 (0.98--1.02)Number of physician visits1.00 (1.00--1.00)1.00 (1.00--1.00)1.00 (1.00--1.00)1.00 (1.00--1.00)[^3][^4][^5]

Personality disorders before and after IMID diagnosis {#sec3-4}
-----------------------------------------------------

After we restricted the study population to individuals with 5 years of data before and after the IMID-index year, we were able to include 12 141 incident cases with IMID, 3766 with IBD, 2190 with MS and 6350 with RA, as well as a matched subgroup of 65 424 persons ([Table 1](#tab01){ref-type="table"}). The characteristics of the IMID and matched subgroups were similar to those of the larger study population from which they were drawn ([Table 1](#tab01){ref-type="table"}).

After age and sex-standardisation, incidence of any PD was higher in all IMID subgroups compared to their matched subgroups in the index year, although this did not reach statistical significance for the MS or RA subgroups ([Table 3](#tab03){ref-type="table"}, [Fig. 2](#fig02){ref-type="fig"}). The incidence of any PD was also consistently higher in the combined IMID subgroup than the matched subgroup during the pre-index and post-index periods ([Table 3](#tab03){ref-type="table"}, [Fig. 2](#fig02){ref-type="fig"}). Table 3.Standardised incidence rate ratios for any personality disorder in disease cohorts (*v*. matched controls), presented 5 years pre-index to 5 years post-indexIncidence rate ratio (95% confidence interval)Combined IMIDIBDMSRA5 years pre-1.29 (0.81--2.06)1.25 (0.54--2.86)2.09 (0.88--4.99)1.15 (0.52--2.55)4 tears pre-**1.61 (1.00--2.61)**1.08 (0.43--2.74)2.24 (0.77--6.51)2.14 (0.99--4.61)3 years pre-**1.81 (1.10--2.95)\*3.04 (1.50--6.19)\***--1.80 (0.77--4.22)2 years pre-**2.24 (1.36--3.70)\***1.87 (0.81--4.31)**3.34 (1.19--9.37)\***1.03 (0.35--3.01)1 year pre-**2.22 (1.37--3.60)\*2.62 (1.32--5.19)\***2.97 (0.71--12.50)**3.86 (1.10--13.55)\***Year 0[^a^](#tfn3_2){ref-type="table-fn"}**2.38 (1.52--3.72)\*4.06 (2.08--7.94)\***2.39 (0.84--6.83)1.54 (0.66--3.63)1 year post-**1.70 (1.02--2.84)\*2.77 (1.16--6.64)\*5.74 (1.65--20.01)\***0.83 (0.34--2.02)2 years post-1.34 (0.79--2.26)1.85 (0.86--3.99)--1.36 (0.51--3.60)3 years post-**1.84 (1.10--3.10)\***1.95 (0.87--4.37)1.60 (0.56--4.62)**2.44 (1.00--5.95)\***4 years post-1.57 (0.96--2.56)**2.17 (1.05--4.49)\***--2.02 (0.55--7.49)5 years post-**2.31 (1.38--3.85)\*2.51 (1.01--6.24)\***--1.48 (0.62--3.55)[^6][^7][^8] Fig. 2.Incidence of any personality disorder per 1,000 person-years, age and sex-standardized to the 2010 Canadian population, in disease cohorts and matched controls, across the 5 years before and 5 years after the index date. Index year is represented by 0. Absent lines are due to suppression.

After adjusting for age, sex, index year, SES, region of residence and number of physician visits, there was no linear change in any PD incidence during the pre-index or post-index periods in the IMID subgroups. No difference in rates of change was observed between the pre-index and post-index periods ([Table 4](#tab04){ref-type="table"}). Table 4.Incidence rate ratios (95% confidence intervals) showing association between personality disorders pre- and post-index date and immune-mediated inflammatory diseaseCohortsModel 1Model 2Combined IMIDYear effect: cases pre-index1.01 (0.89--1.15)1.01 (0.89--1.15)Year effect: cases post-index0.98 (0.89--1.08)0.98 (0.89--1.08)Post-pre ratio: cases0.97 (0.82--1.14)0.97 (0.83--1.13)Year effect: controls pre-index**0.91 (0.84**--**0.98)\***0.96 (0.92--1.01)Year effect: controls post-index0.97 (0.91--1.03)1.00 (0.95--1.05)Post-pre ratio: controls1.07 (0.97--1.18)1.04 (0.95--1.13)Case ratio/control ratio0.91 (0.75--1.10)0.93 (0.78--1.12)Inflammatory bowel diseaseYear effect: cases pre-index1.18 (0.96--1.46)1.19 (0.97--1.46)Year effect: cases post-index0.93 (0.80--1.08)0.93 (0.80--1.08)Post-pre ratio: cases0.79 (0.61--1.02)0.78 (0.61--1.01)Year effect: controls pre-index0.89 (0.79--1.01)0.92 (0.85--1.00)Year effect: controls post-index0.99 (0.89--1.09)1.00 (0.92--1.10)Post-pre ratio: controls1.10 (0.94--1.29)1.09 (0.94--1.27)Case ratio/control ratio**0.71 (0.53**--**0.97)\*0.72 (0.53**--**0.97)\***Multiple sclerosisYear effect: cases pre-index0.96 (0.77--1.21)0.97 (0.77--1.22)Year effect: cases post-index0.86 (0.69--1.07)0.85 (0.69--1.06)Post-pre ratio: cases0.89 (0.65--1.23)0.88 (0.64--1.21)Year effect: controls pre-index0.86 (0.73--1.01)0.94 (0.85--1.05)Year effect: controls post-index0.96 (0.84--1.08)1.00 (0.90--1.12)Post-pre ratio: controls1.11 (0.91--1.36)1.06 (0.88--1.29)Case ratio/control ratio0.80 (0.55--1.17)0.83 (0.58--1.20)Rheumatoid arthritisYear effect: cases pre-index0.88 (0.71--1.09)0.88 (0.72--1.08)Year effect: cases post-index1.11 (0.95--1.30)1.11 (0.95--1.3)Post-pre ratio: cases1.26 (0.97--1.64)1.27 (0.98--1.64)Year effect: controls pre-index0.92 (0.82--1.03)0.99 (0.93--1.06)Year effect: controls post-index0.95 (0.87--1.03)0.98 (0.92--1.06)Post-pre ratio: controls1.03 (0.89--1.18)0.99 (0.87--1.12)Case ratio/control ratio1.23 (0.91--1.65)1.28 (0.96--1.70)[^9][^10]

Discussion {#sec4}
==========

Using population-based administrative data for the full study population, we found that the incidence of any PD was elevated in the IMID population relative to matched controls, regardless of the specific IMID condition; the same was true for prevalence. The elevated incidence of any PD was consistent over study years. Younger age, lower SES and urban residence were associated with an increased incidence of any PD. In the restricted subgroup, trends in the incidence of any PD did not differ before and after the IMID diagnosis.

Several possible explanations exist for the increased incidence of PDs in IMID. The increased incidence before IMID diagnosis, even after adjusting for number of physician visits, suggests that the findings do not reflect surveillance bias (i.e., increased probability of detection due to increased observation). A prodromal syndrome characterised by pathological personality patterns is possible, but the stability of our incidence rates argues against this explanation. The most compelling explanation for our results is shared risk factors. Poor psychosocial health, for example, encompassing variables such as past sexual abuse and violence, has been associated with personality dysfunction (Battle *et al*., [@ref7]), as well as IBD (Caplan *et al*., [@ref13]), MS (Spitzer *et al*., [@ref61]) and arthritic diseases (Brennan-Olsen *et al*., [@ref12]). A pro-inflammatory state secondary to chronic stress exposure (Miller *et al*., [@ref47]) could also play a role (Cătană *et al*., [@ref14]; Li *et al*., [@ref37]; Oglodek *et al*., [@ref50]; Bartlett *et al*., [@ref6]). Shared genetic markers (Kendler *et al*., [@ref33]; Liu *et al*., [@ref39]; Yarwood *et al*., [@ref70]; Parnell and Booth, [@ref52]) may also contribute to the development of PDs and IMID. In such situations, we would expect increases in incidence to remain stable over time given inter-individual variance in the timing of the mental and physical health presentations. This phenomenon, previously supported in the context of comorbid anxiety disorders and chronic pain (Asmundson *et al*., [@ref4]), appears to be demonstrated with our results. The search for common risk factors is an important area for future research on psychiatric comorbidity in IMID populations, as it provides a means of understanding potential mechanisms for the occurrence and maintenance of comorbidity.

There may also be a form of mutual maintenance at play for all IMID groups, similar to that first discussed between chronic health conditions and post-traumatic stress disorder (Sharp and Harvey, [@ref59]). Any of the disease experiences discussed above may amplify hyper-controlled or emotionally dysregulated personality structures, such as those corresponding with obsessive-compulsive PD (OCPD) and borderline PD (BPD). Personality-pathology related outcomes, such as interpersonal difficulties, impede healthy adjustment to illness (Stanton *et al*., [@ref62]), interact adversely with self-concept in the context of chronic disease (Juth *et al*., [@ref31]) and worsen disability (Evers *et al*., [@ref21]). Therefore, future studies should explore the specific nature of personality pathology in IMID populations, the relevance of IMID-specific disease experiences and the role of mutual maintenance in this comorbidity.

Lower SES and urban living have been consistently associated with poorer mental health (Miech *et al*., [@ref46]; Judd *et al*., [@ref30]). The former may reflect increased stressors (e.g., lower finances, less social supports) or poorer health behaviours such as smoking or unhealthy diet (Wadsworth, [@ref67]). The latter may reflect relocation into urban settings upon personal need for greater access to mental health supports (Brems *et al*., [@ref11]) as well as mental health stigma interfering with the access of supports in rural regions (Rost *et al*., [@ref56]). While individuals between the ages of 45 and 64 years were at a reduced risk of a PD diagnosis, this may be explained by the fact that some PD symptomatology, such as that associated with BPD, presents less explicitly with age, therefore becoming harder to detect (Van Alphen *et al*., [@ref65]). Relatedly, assessment of personality dysfunction across the lifetime can be affected by clinicians\' relatively limited exposure to, and understanding, of healthy aging, thereby confounding norm comparisons (Zweig, [@ref71]). Alternatively, this finding may reflect a true effect, given evidence that mental health symptoms improve with age (Reynolds *et al*., [@ref54]). Significant findings for the oldest age group may simply be undetected due to a lack of statistical power. Sex was not a predictor of PDs in our study, but this may have been because we combined all PDs and personality pathology demonstrates condition-specific gender differences. For example, schizoid PD and OCPD are more common in males, whereas dependent PD and BPD are more commonly diagnosed in females (Paris, [@ref51]).

Clinicians\' recognition of the elevated rates of PD diagnoses across IMID groups is important due to the inherent interpersonal difficulties associated with personality pathology (APA, [@ref3]). Given the need for medical supports among those with chronic physical conditions, this comorbid population is likely to have greater difficulties navigating the health care system (Van Alphen *et al*., [@ref65]). Our findings highlight the need for increased supports for these individuals. Examples of these supports might include interpersonal effectiveness training (e.g., assertiveness skills) and distress tolerance (e.g., radical acceptance), hallmarks of dialectical behaviour therapy (DBT; Linehan, [@ref38]). In further support of this approach, DBT has previously been postulated as an intervention that may be appropriate for difficult patients reliant on the medical system (Huffman *et al*., [@ref27]). Future research directions should explore assessment considerations and treatment options in this vulnerable population.

Although our study strengths include large sample size, population-based design and long study period, there are limitations. PDs were identified using hospital and physician claims, therefore diagnoses by non-physician providers may not have been captured. Nonetheless, we expect this potential bias to be non-differential between groups. Nuances in the presentation of personality pathology in the context of physical health conditions may further complicate assessment; for example, BPD in medical settings has been shown to present less characteristically (i.e., graphic self-harm, labile mood) and more somatically (i.e., pain sensitivity, somatic preoccupation; Sansone and Sansone, [@ref57]). Relatedly, given an association between BPD and pain catastrophising (Sansone *et al*., [@ref58]), the possibility of a reporting bias to physicians cannot be dismissed; yet notably, this association appears to be more related to depressive experience as opposed to personality structure per se (Mun *et al*., [@ref49]). We focused on PDs, yet less severe pathological personality presentations would not have been captured. We were unable to differentiate between specific PDs. Finally, caution should be applied to interpretation regarding the individual IMID groups, given some small cell sizes.

In summary, persons with IMIDs are at an increased risk of a PD, regardless of the specific IMID. Elevated comorbidity rates may relate to shared risk factors between IMID and PDs but this requires further investigation. PDs warrant greater attention in IMID research and in the care of IMID patients, due to the potential for improving our understanding of the aetiology and treatment of these conditions.
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[^1]: IMID, immune-mediated inflammatory diseases; IBD, inflammatory bowel disease; MS, multiple sclerosis; RA, rheumatoid arthritis.

[^2]: *Note*. Adapted from Marrie *et al*. ([@ref42]).

[^3]: Adjusted for age, sex, year, socioeconomic status, region and number of physician visits.

[^4]: \**p* \< 0.05.

[^5]: Bold indicates statistical significance.

[^6]: IMID, immune-mediated inflammatory disease, IBD, inflammatory bowel disease, MS, multiple sclerosis, RA, rheumatoid arthritis.

[^7]: Index year is represented by 0. Matched controls as reference group, \**p* \< 0.05.

[^8]: Bold indicates statistical significance.

[^9]: The year variable assesses whether there is an annual linear increase in incidence in the cohort (cases or controls) and period (pre-index or post-index) of interest. Post-pre ratio compares the year effect in the post-index *v*. pre-index periods. A ratio \<1 indicates the rise in incidence was greater in the pre-index period than the post-index period whereas a ratio indicates the yearly rise in incidence is greater in the post-index than the pre-index period. The case ratio/control ratio variable assesses whether the pre-post ratios differ in the cases and controls. Model 1, unadjusted; Model 2, adjusted for sex, age, index year, urban/rural, SEF12 quintiles; Model 3, adjusted for sex, age, index year, urban/rural, SEF12 quintiles, non-psychiatric physician visits, \**p* \< 0.05.

[^10]: Bold indicates statistical significance.
